Evidence map›Paper›PMID 35283667›Full record

ReviewCurrent genomics2021

Chemogenomic Approaches for Revealing Drug Target Interactions in Drug Discovery.

Harshita Bhargava, Amita Sharma, Prashanth Suravajhala

Open access · greenAbstract readReview
In one paragraph

Review in Current genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Harshita BhargavaDepartment of Computer Science & IT, IIS (Deemed to be University), Jaipur, India.
Amita SharmaDepartment of Computer Science & IT, IIS (Deemed to be University), Jaipur, India.
Prashanth SuravajhalaBioclues.org, Kukatpally, Hyderabad, 500072, India.
Inspiration Innovation Synergy University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The drug discovery process has been a crucial and cost-intensive process. This cost is not only monetary but also involves risks, time, and labour that are incurred while introducing a drug in the market. In order to reduce this cost and the risks associated with the drugs that may result in severe side effects, the in silico methods have gained popularity in recent years. These methods have had a significant impact on not only drug discovery but also the related areas such as drug repositioning, drug-target interaction prediction, drug side effect prediction, personalised medicine,

Indexed as

Chemogenomic approacheschemogenomic methodsdrug discoverydrug targetin silico methodspersonalised medicine

Identifiers

PMID35283667
PMCPMC8844939
OpenAlexW3200972889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.